Recursion names Vicki Goodman as CMO

Recursion (Nasdaq: RXRX) said on Wednesday that it had named Vicki Goodman as chief medical officer, effective April 6, 2026, succeeding David Mauro. Goodman had more than two decades of experience in ...
Zacks Investment Research on MSN

Recursion Pharmaceuticals (RXRX) advances while market declines: Some information for investors

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.37, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.28%. Elsewhere, the Dow ...
Investing

Recursion Pharmaceuticals files prospectus supplement

Recursion Pharmaceuticals , Inc. (NASDAQ:RXRX), currently trading at $4.32 and showing signs of being undervalued according to InvestingPro Fair Value metrics, has announced the filing of a prospectus ...
bernama

Recursion: Non-antibiotic Treatment For Recurrent C. diff Infection Enters Phase 2 Trial

KUALA LUMPUR, Oct 23 (Bernama) -- Recursion, a clinical stage TechBio company, announced the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral ...